RxDoctor Payments Data

Richard Lutz

Clinical Genetics (M.D.) · Omaha, NENPI 1992755326

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 52.2% of the total.

$314in general payments, 2019–2025

Across 15 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biomarin Pharmaceutical Inc.$164
  • CSL Behring$62
  • Shire North American Group Inc$39
  • Amgen$24
  • Amicus Therapeutics, Inc.$16
  • Travere Therapeutics, Inc.$10
$495,254in research payments, 2019–2025

Across 33 payments — averaging $15,008 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$322K
  • Shire North American Group Inc$173K

What the payments were for

  • Food & beverage$30597%
  • Education$103%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical genetics (m.d.) providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Other clinical genetics (m.d.) in Omaha

Where these figures come from

Is this you, or does something look wrong? →